famotidine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histamine-H2-receptor antagonists, cimetidine derivatives 1129 76824-35-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • famotidine
  • agufam
  • amfamox
  • antodine
  • apogastine
  • bestidine
  • brolin
  • cepal
  • digervin
  • dispromil
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. Computer-aided, structure-based, virtual screening of libraries of compounds against SARS-CoV-2 proteins suggested potential for famotidine to interact with viral proteases in-volved in coronavirus replication. HOWEVER, there is no clinical trial evidence supporting efficacy or safety for treatment of COVID-19.
  • Molecular weight: 337.44
  • Formula: C8H15N7O2S3
  • CLOGP: -0.86
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 6
  • TPSA: 170.83
  • ALOGS: -3.48
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 mg O
40 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 67 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.98 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.84 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 15, 1986 FDA VALEANT PHARMS NORTH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 287.13 9.21 703 105122 677135 45903102
Rheumatoid arthritis 224.84 9.21 133 105692 240082 46340155
Contraindicated product administered 136.78 9.21 12 105813 79935 46500302
Drug intolerance 131.10 9.21 86 105739 146963 46433274
Synovitis 116.92 9.21 5 105820 61070 46519167
Hepatic function abnormal 110.08 9.21 242 105583 34179 46546058
Treatment failure 109.73 9.21 37 105788 93050 46487187
Gastrooesophageal reflux disease 102.66 9.21 386 105439 73958 46506279
Chronic kidney disease 99.02 9.21 258 105567 40613 46539624
Joint swelling 94.32 9.21 144 105681 165929 46414308
Pneumonia aspiration 91.92 9.21 214 105611 31391 46548846
Drug abuse 88.41 9.21 18 105807 63390 46516847
Toxicity to various agents 86.37 9.21 223 105602 211543 46368694
White blood cell count decreased 81.31 9.21 483 105342 111748 46468489
Platelet count decreased 80.68 9.21 443 105382 99581 46480656
Therapeutic product effect decreased 70.00 9.21 51 105774 82550 46497687
Disseminated intravascular coagulation 58.93 9.21 132 105693 18873 46561364
Off label use 57.14 9.21 568 105257 379273 46200964
Arthropathy 54.53 9.21 67 105758 84633 46495604
Completed suicide 51.14 9.21 165 105660 145755 46434482
Cholecystitis chronic 50.90 9.21 88 105737 10411 46569826
Aspartate aminotransferase increased 50.87 9.21 329 105496 78371 46501866
Systemic lupus erythematosus 50.50 9.21 44 105781 65136 46515101
Hand deformity 49.92 9.21 9 105816 34565 46545672
Neutrophil count decreased 48.37 9.21 211 105614 43215 46537022
Maternal exposure during pregnancy 47.34 9.21 101 105724 102448 46477789
Arthralgia 47.29 9.21 564 105261 364039 46216198
Liver disorder 46.98 9.21 188 105637 37058 46543179
Drug hypersensitivity 45.79 9.21 344 105481 243481 46336756
Blood lactate dehydrogenase increased 44.20 9.21 124 105701 20376 46559861
Lower respiratory tract infection 44.13 9.21 36 105789 55053 46525184
Hepatocellular injury 44.13 9.21 7 105818 29515 46550722
Therapeutic product effect incomplete 43.15 9.21 69 105756 78084 46502153
Glossodynia 40.81 9.21 25 105800 44348 46535889
Dehydration 39.92 9.21 544 105281 158996 46421241
General physical health deterioration 39.11 9.21 133 105692 115636 46464601
Alanine aminotransferase increased 39.11 9.21 338 105487 88113 46492124
Interstitial lung disease 36.38 9.21 228 105597 53721 46526516
Angioedema 35.64 9.21 180 105645 39162 46541075
Musculoskeletal stiffness 35.59 9.21 109 105716 97884 46482353
Alopecia 34.47 9.21 221 105604 162193 46418044
Torsade de pointes 33.92 9.21 81 105744 12073 46568164
Butterfly rash 33.11 9.21 23 105802 951 46579286
Enterocolitis 32.96 9.21 54 105771 6114 46574123
Upper respiratory tract inflammation 32.88 9.21 36 105789 2759 46577478
Flushing 31.27 9.21 252 105573 64362 46515875
Overdose 29.36 9.21 125 105700 101854 46478383
Cerebral infarction 27.92 9.21 116 105709 23250 46556987
Exposure during pregnancy 26.83 9.21 140 105685 108072 46472165
End stage renal disease 26.80 9.21 48 105777 5838 46574399
Urticaria 26.27 9.21 394 105431 117498 46462739
Mental status changes 25.69 9.21 161 105664 37927 46542310
Product use issue 25.45 9.21 119 105706 94525 46485712
Foetal exposure during pregnancy 24.74 9.21 20 105805 30727 46549510
Gallbladder disorder 23.42 9.21 90 105735 17408 46562829
Injection site pain 22.62 9.21 146 105679 107006 46473231
Mobility decreased 22.28 9.21 67 105758 60527 46519710
Lip swelling 22.16 9.21 115 105710 25280 46554957
Drug resistance 22.09 9.21 6 105819 17362 46562875
Haemorrhage subcutaneous 22.07 9.21 30 105795 2876 46577361
Anaphylactic reaction 21.94 9.21 200 105625 52912 46527325
Hepatic enzyme increased 21.30 9.21 104 105721 81683 46498554
Red blood cell sedimentation rate increased 20.90 9.21 13 105812 22876 46557361
Renal injury 20.85 9.21 58 105767 9483 46570754
Knee arthroplasty 20.84 9.21 14 105811 23651 46556586
Chest discomfort 20.62 9.21 303 105522 89966 46490271
Pyrexia 20.58 9.21 977 104848 347825 46232412
Periorbital oedema 20.34 9.21 39 105786 4996 46575241
Drug eruption 20.31 9.21 99 105726 21230 46559007
Febrile neutropenia 20.21 9.21 314 105511 94313 46485924
Basophil count decreased 20.07 9.21 8 105817 101 46580136
Wound 19.87 9.21 42 105783 42760 46537477
Lactic acidosis 19.61 9.21 29 105796 33880 46546357
Lymphocyte stimulation test positive 19.39 9.21 14 105811 616 46579621
Drug interaction 19.27 9.21 334 105491 202760 46377477
Psoriatic arthropathy 19.25 9.21 33 105792 36346 46543891
Injection site reaction 18.99 9.21 51 105774 47798 46532439
Biliary dyskinesia 18.64 9.21 27 105798 2746 46577491
Device expulsion 18.56 9.21 21 105804 27521 46552716
Acquired haemophilia 18.52 9.21 16 105809 915 46579322
Constipation 18.44 9.21 521 105304 173576 46406661
Acute respiratory failure 18.32 9.21 121 105704 29017 46551220
Infective pulmonary exacerbation of cystic fibrosis 18.25 9.21 60 105765 10747 46569490
Cytokine release syndrome 17.94 9.21 42 105783 6181 46574056
Ventricular tachycardia 17.80 9.21 81 105744 16886 46563351
Pericarditis 17.52 9.21 17 105808 23910 46556327
Urinary tract infection 17.30 9.21 636 105189 219630 46360607
Pain 17.19 9.21 895 104930 476053 46104184
Loss of personal independence in daily activities 17.13 9.21 69 105756 57114 46523123
Arthritis 16.49 9.21 105 105720 77211 46503026
Dyspepsia 16.09 9.21 231 105594 68241 46511996
Rebound acid hypersecretion 15.78 9.21 9 105816 262 46579975
Blood alkaline phosphatase increased 15.77 9.21 148 105677 39461 46540776
Blood pressure fluctuation 15.77 9.21 28 105797 30420 46549817
Serotonin syndrome 15.75 9.21 19 105806 24201 46556036
Injection site bruising 15.69 9.21 36 105789 35600 46544637
Premature baby 15.57 9.21 11 105814 18101 46562136
Neuropathy peripheral 15.55 9.21 291 105534 90602 46489635
Cystitis noninfective 15.51 9.21 14 105811 849 46579388
Breast adenoma 15.39 9.21 5 105820 33 46580204
Cholinergic syndrome 15.31 9.21 10 105815 373 46579864
Lupus hepatitis 15.27 9.21 5 105820 34 46580203
Gallbladder injury 14.97 9.21 17 105808 1357 46578880
Intentional self-injury 14.63 9.21 20 105805 24146 46556091
Hypoxia 14.29 9.21 180 105645 51658 46528579
Respiratory alkalosis 14.27 9.21 23 105802 2568 46577669
Cytomegalovirus enterocolitis 14.06 9.21 11 105814 547 46579690
Allergy test positive 14.04 9.21 9 105816 325 46579912
Burkholderia test positive 13.88 9.21 6 105819 94 46580143
Hepatotoxicity 13.87 9.21 22 105803 24987 46555250
Disease progression 13.83 9.21 287 105538 91013 46489224
Chest pain 13.81 9.21 509 105316 175815 46404422
Cholecystitis acute 13.78 9.21 43 105782 7495 46572742
Psoriasis 13.74 9.21 113 105712 78491 46501746
Cholestasis 13.68 9.21 25 105800 26868 46553369
Therapeutic response decreased 13.60 9.21 51 105774 43094 46537143
Congenital neuropathy 13.59 9.21 4 105821 18 46580219
Granulocytopenia 13.50 9.21 34 105791 5239 46574998
Pyuria 13.33 9.21 18 105807 1715 46578522
Small intestinal obstruction 13.27 9.21 72 105753 16100 46564137
White blood cell count increased 13.26 9.21 156 105669 44063 46536174
Helicobacter infection 13.25 9.21 5 105820 11731 46568506
Hip arthroplasty 13.11 9.21 13 105812 18099 46562138
Pneumonia 13.08 9.21 1006 104819 375314 46204923
Throat irritation 13.05 9.21 111 105714 28790 46551447
Brain natriuretic peptide increased 12.98 9.21 31 105794 4619 46575618
Decreased appetite 12.94 9.21 550 105275 193286 46386951
Fibromyalgia 12.92 9.21 41 105784 36422 46543815
Victim of chemical submission 12.73 9.21 8 105817 279 46579958
Ill-defined disorder 12.72 9.21 26 105799 26801 46553436
Diarrhoea 12.70 9.21 1451 104374 558151 46022086
Full blood count decreased 12.63 9.21 90 105735 22121 46558116
Hypoparathyroidism 12.54 9.21 11 105814 642 46579595
Haematocrit decreased 12.50 9.21 128 105697 34929 46545308
Protein total decreased 12.49 9.21 34 105791 5489 46574748
Hospice care 12.38 9.21 33 105792 5262 46574975
Dizziness 12.32 9.21 913 104912 339501 46240736
Erythema multiforme 12.25 9.21 49 105776 9655 46570582
Tubulointerstitial nephritis 12.24 9.21 66 105759 14722 46565515
Asteatosis 12.14 9.21 5 105820 69 46580168
Gastritis 12.01 9.21 125 105700 34253 46545984
Hypoalbuminaemia 11.88 9.21 50 105775 10077 46570160
Ovarian cancer recurrent 11.86 9.21 13 105812 998 46579239
Osteoarthritis 11.85 9.21 87 105738 61938 46518299
Blood potassium decreased 11.73 9.21 135 105690 37928 46542309
Musculoskeletal pain 11.72 9.21 102 105723 70026 46510211
Rheumatoid nodule 11.69 9.21 3 105822 9017 46571220
Xanthogranuloma 11.68 9.21 3 105822 7 46580230
Anaphylactoid reaction 11.67 9.21 25 105800 3466 46576771
Hyperuricaemia 11.64 9.21 30 105795 4687 46575550
Neurological examination abnormal 11.43 9.21 7 105818 233 46580004
Cholelithiasis 11.39 9.21 136 105689 38545 46541692
Palmar erythema 11.31 9.21 15 105810 1405 46578832
Putamen haemorrhage 11.13 9.21 6 105819 156 46580081
Injury 10.93 9.21 150 105675 43877 46536360
Intraductal papillary breast neoplasm 10.90 9.21 3 105822 10 46580227
Blood bilirubin increased 10.87 9.21 122 105703 34062 46546175
Extrapyramidal disorder 10.85 9.21 6 105819 11262 46568975
Reticulocyte count increased 10.74 9.21 10 105815 631 46579606
Coma 10.74 9.21 189 105636 58160 46522077
Blood urea increased 10.74 9.21 96 105729 25256 46554981
Dyspnoea 10.66 9.21 1329 104496 514219 46066018
Abdominal distension 10.60 9.21 229 105596 73122 46507115
Hereditary angioedema 10.58 9.21 32 105793 5484 46574753
Hyperlipidaemia 10.47 9.21 75 105750 18464 46561773
Impaired work ability 10.44 9.21 8 105817 12628 46567609
Pupils unequal 10.40 9.21 14 105811 1330 46578907
Gastrointestinal haemorrhage 10.37 9.21 239 105586 77134 46503103
Pityriasis lichenoides et varioliformis acuta 10.37 9.21 4 105821 46 46580191
Haemolytic anaemia 10.33 9.21 47 105778 9795 46570442
Therapy non-responder 10.33 9.21 53 105772 41099 46539138
Reticulocyte percentage increased 10.28 9.21 3 105822 13 46580224
Throat tightness 10.25 9.21 81 105744 20558 46559679
Allergic transfusion reaction 10.22 9.21 4 105821 48 46580189
Dizziness postural 10.19 9.21 35 105790 6411 46573826
Nausea 10.14 9.21 1738 104087 685716 45894521
Coronary artery dissection 10.12 9.21 10 105815 680 46579557
Vascular resistance systemic decreased 10.11 9.21 5 105820 108 46580129
Myocarditis infectious 10.10 9.21 3 105822 14 46580223
Wrong technique in product usage process 10.08 9.21 77 105748 54345 46525892
Atrioventricular block complete 10.02 9.21 39 105786 7588 46572649
Histamine level increased 9.93 9.21 3 105822 15 46580222
Therapeutic hypothermia 9.93 9.21 3 105822 15 46580222
Ileus 9.83 9.21 60 105765 14004 46566233
Ovarian cancer 9.76 9.21 32 105793 5723 46574514
Blood magnesium decreased 9.75 9.21 50 105775 10942 46569295
Red blood cell count decreased 9.74 9.21 115 105710 32508 46547729
Colitis ischaemic 9.63 9.21 47 105778 10085 46570152
Blood creatine phosphokinase MB increased 9.55 9.21 13 105812 1248 46578989
Light chain analysis increased 9.54 9.21 12 105813 1066 46579171
Injection site pruritus 9.52 9.21 52 105773 39691 46540546
Medication error 9.45 9.21 37 105788 30874 46549363
Abortion spontaneous 9.44 9.21 59 105766 43587 46536650
Lymphocyte count decreased 9.39 9.21 94 105731 25495 46554742
Urticaria chronic 9.39 9.21 8 105817 449 46579788
Near drowning 9.34 9.21 3 105822 19 46580218
COVID-19 pneumonia 9.33 9.21 22 105803 3253 46576984
Neuroleptic malignant syndrome 9.24 9.21 7 105818 11115 46569122

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 141.01 9.90 319 74584 41626 29835949
Drug ineffective 139.37 9.90 415 74488 339972 29537603
Drug abuse 127.82 9.90 25 74878 82047 29795528
Liver disorder 92.12 9.90 219 74684 29503 29848072
Platelet count decreased 91.56 9.90 514 74389 105615 29771960
Toxicity to various agents 85.20 9.90 199 74704 176984 29700591
Completed suicide 84.07 9.90 75 74828 99417 29778158
Aspartate aminotransferase increased 81.95 9.90 345 74558 63077 29814498
Alanine aminotransferase increased 81.63 9.90 385 74518 73891 29803684
White blood cell count decreased 70.00 9.90 403 74500 83544 29794031
Disseminated intravascular coagulation 68.30 9.90 163 74740 22008 29855567
Drug interaction 57.56 9.90 280 74623 199288 29678287
Off label use 52.75 9.90 386 74517 248904 29628671
General physical health deterioration 48.16 9.90 112 74791 99832 29777743
Neutrophil count decreased 47.28 9.90 221 74682 42233 29835342
Blood lactate dehydrogenase increased 45.66 9.90 134 74769 20467 29857108
Chronic kidney disease 44.38 9.90 200 74703 37638 29839937
Interstitial lung disease 43.79 9.90 279 74624 59918 29817657
Rheumatoid arthritis 38.58 9.90 28 74875 41169 29836406
Drug resistance 36.23 9.90 4 74899 20129 29857446
Blood alkaline phosphatase increased 35.12 9.90 164 74739 31323 29846252
Upper respiratory tract inflammation 34.80 9.90 32 74871 1799 29875776
Cerebral infarction 32.89 9.90 142 74761 26231 29851344
Overdose 32.05 9.90 106 74797 84231 29793344
Product use in unapproved indication 32.05 9.90 87 74816 73606 29803969
Treatment failure 30.65 9.90 25 74878 34654 29842921
Lymphocyte stimulation test positive 28.51 9.90 21 74882 862 29876713
Contraindicated product administered 27.33 9.90 5 74898 17226 29860349
Foetal exposure during pregnancy 26.36 9.90 32 74871 36839 29840736
Infusion related reaction 24.71 9.90 180 74723 40384 29837191
Decreased appetite 23.88 9.90 516 74387 149394 29728181
Psoriasis 23.51 9.90 44 74859 42462 29835113
Pyrexia 23.25 9.90 928 73975 293561 29584014
Drug intolerance 22.40 9.90 50 74853 45241 29832334
End stage renal disease 22.18 9.90 54 74849 7381 29870194
Pneumonitis 21.04 9.90 129 74774 27325 29850250
Blood creatine phosphokinase MB increased 20.68 9.90 25 74878 1931 29875644
Pneumonia bacterial 20.67 9.90 61 74842 9342 29868233
Haematocrit decreased 20.32 9.90 139 74764 30560 29847015
Blood albumin decreased 19.88 9.90 73 74830 12519 29865056
Erythema multiforme 19.70 9.90 54 74849 7931 29869644
Blood urea increased 19.54 9.90 140 74763 31241 29846334
Blood bilirubin increased 19.21 9.90 157 74746 36479 29841096
Pneumonia 19.14 9.90 1020 73883 333286 29544289
Hypoxia 18.48 9.90 192 74711 47662 29829913
Pneumonia aspiration 18.27 9.90 159 74744 37621 29839954
Intentional product misuse 18.21 9.90 37 74866 34630 29842945
Therapeutic product effect incomplete 17.86 9.90 36 74867 33798 29843777
Acute respiratory failure 17.67 9.90 118 74785 25732 29851843
Lactic acidosis 17.54 9.90 32 74871 31181 29846394
Intentional overdose 17.26 9.90 50 74853 41431 29836144
Extrapyramidal disorder 17.18 9.90 3 74900 10690 29866885
Ventricular tachycardia 16.97 9.90 110 74793 23752 29853823
Human ehrlichiosis 16.94 9.90 9 74894 205 29877370
PO2 increased 16.86 9.90 13 74890 572 29877003
Cholangitis acute 16.28 9.90 14 74889 720 29876855
Lower respiratory tract infection 16.28 9.90 26 74877 26688 29850887
Enterocolitis 16.27 9.90 45 74858 6642 29870933
Mast cell activation syndrome 16.18 9.90 7 74896 99 29877476
Rash 16.11 9.90 609 74294 191280 29686295
Gastrointestinal mucosal necrosis 16.09 9.90 8 74895 158 29877417
Wound secretion 15.84 9.90 25 74878 2483 29875092
Infective pulmonary exacerbation of cystic fibrosis 15.52 9.90 52 74851 8520 29869055
Hepatocellular injury 15.33 9.90 25 74878 25446 29852129
Constipation 15.28 9.90 380 74523 112526 29765049
Torsade de pointes 15.20 9.90 46 74857 7144 29870431
Glossectomy 14.98 9.90 3 74900 0 29877575
Sepsis 14.61 9.90 474 74429 145921 29731654
CADASIL 14.39 9.90 6 74897 77 29877498
Ultrasound skull abnormal 14.39 9.90 6 74897 77 29877498
Intentional product use issue 14.39 9.90 45 74858 36395 29841180
Magnetic resonance imaging spinal abnormal 14.12 9.90 6 74897 81 29877494
Renal impairment 14.10 9.90 292 74611 83892 29793683
Respiratory failure 14.00 9.90 340 74563 100302 29777273
Visual evoked potentials abnormal 13.80 9.90 6 74897 86 29877489
Convulsions local 13.78 9.90 4 74899 15 29877560
Gastrooesophageal reflux disease 13.70 9.90 132 74771 32123 29845452
Convulsive threshold lowered 13.62 9.90 11 74892 518 29877057
Cytokine release syndrome 13.57 9.90 55 74848 9878 29867697
Joint swelling 13.41 9.90 66 74837 46880 29830695
Physical examination abnormal 13.20 9.90 6 74897 96 29877479
Psychotic disorder 13.05 9.90 21 74882 21494 29856081
Anal erosion 13.03 9.90 4 74899 19 29877556
Protein total decreased 13.02 9.90 34 74869 4851 29872724
Febrile neutropenia 12.96 9.90 354 74549 106339 29771236
Urticaria 12.90 9.90 200 74703 54406 29823169
Pneumonia staphylococcal 12.89 9.90 25 74878 2926 29874649
Central nervous system inflammation 12.88 9.90 6 74897 102 29877473
Catheter site haemorrhage 12.83 9.90 21 74882 2151 29875424
Burkholderia test positive 12.80 9.90 10 74893 449 29877126
Depressed level of consciousness 12.75 9.90 149 74754 38073 29839502
Double stranded DNULL antibody positive 12.72 9.90 6 74897 105 29877470
Death 12.69 9.90 748 74155 356535 29521040
Rash maculo-papular 12.62 9.90 28 74875 25390 29852185
Ventricular flutter 12.45 9.90 5 74898 58 29877517
Blood pressure decreased 12.13 9.90 175 74728 46900 29830675
Eczema asteatotic 12.10 9.90 7 74896 189 29877386
Hypertensive crisis 12.08 9.90 3 74900 8354 29869221
Post procedural haematoma 12.04 9.90 17 74886 1530 29876045
Sputum retention 11.99 9.90 10 74893 493 29877082
Cerebral microangiopathy 11.97 9.90 7 74896 193 29877382
Conduction disorder 11.71 9.90 19 74884 1932 29875643
Saccadic eye movement 11.52 9.90 6 74897 131 29877444
Ejaculation delayed 11.44 9.90 7 74896 210 29877365
Jaundice hepatocellular 11.42 9.90 5 74898 73 29877502
Haemorrhagic diathesis 11.30 9.90 23 74880 2788 29874787
Tunnel vision 11.29 9.90 9 74894 416 29877159
White blood cell count increased 11.24 9.90 150 74753 39523 29838052
Hiccups 11.15 9.90 50 74853 9384 29868191
Polyneuropathy 11.11 9.90 8 74895 11815 29865760
Musculoskeletal stiffness 11.10 9.90 49 74854 35832 29841743
Hepatitis fulminant 11.10 9.90 28 74875 3913 29873662
Hyperuricaemia 10.95 9.90 42 74861 7352 29870223
Stevens-Johnson syndrome 10.74 9.90 78 74825 17478 29860097
Blood pH decreased 10.71 9.90 20 74883 2275 29875300
Inappropriate schedule of product administration 10.69 9.90 57 74846 39671 29837904
Pancreatic enlargement 10.62 9.90 5 74898 87 29877488
Cholestasis 10.43 9.90 30 74873 24920 29852655
Coma 10.36 9.90 59 74844 40390 29837185
Paraneoplastic syndrome 10.33 9.90 9 74894 471 29877104
BRASH syndrome 10.31 9.90 4 74899 42 29877533
Inappropriate antidiuretic hormone secretion 10.27 9.90 56 74847 11366 29866209
Staphylococcal sepsis 10.26 9.90 49 74854 9442 29868133
Oral pruritus 10.19 9.90 7 74896 257 29877318
Arthropathy 10.15 9.90 23 74880 20704 29856871
Drug dependence 10.13 9.90 24 74879 21271 29856304
Urine osmolarity decreased 10.07 9.90 4 74899 45 29877530
Progressive multifocal leukoencephalopathy 10.01 9.90 5 74898 9008 29868567
Aortic rupture 9.95 9.90 5 74898 101 29877474
Psoriatic arthropathy 9.93 9.90 15 74888 15746 29861829

Pharmacologic Action:

SourceCodeDescription
ATC A02BA03 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
H2-receptor antagonists
ATC A02BA53 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
H2-receptor antagonists
FDA MoA N0000000151 Histamine H2 Receptor Antagonists
FDA EPC N0000175784 Histamine-2 Receptor Antagonist
CHEBI has role CHEBI:37961 h2-receptor blockers
CHEBI has role CHEBI:49201 anti-ulcer agents
CHEBI has role CHEBI:50183 cytochrome p450 inhibitor
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006635 Histamine H2 Antagonists
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Heartburn indication 16331000
Erosive esophagitis indication 40719004
Duodenal ulcer disease indication 51868009 DOID:1724
Zollinger-Ellison syndrome indication 53132006 DOID:0050782
Peptic reflux disease indication 57643001
Indigestion indication 162031009
Gastroesophageal reflux disease indication 235595009 DOID:8534
Gastric ulcer indication 397825006 DOID:10808
Dyspepsia Prevention indication
Maintenance of Healing Duodenal Ulcer indication
Heartburn Prevention indication
Upper gastrointestinal hemorrhage off-label use 37372002
Prevention of Stress Ulcer off-label use
Constipation contraindication 14760008 DOID:2089
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
Diarrhea contraindication 62315008
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Impaired renal function disorder contraindication 197663003
Osteolysis contraindication 203522001
Disease of liver contraindication 235856003 DOID:409
Malignant tumor of stomach contraindication 363349007 DOID:10534

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.84 acidic
pKa2 12.0 acidic
pKa3 6.97 Basic
pKa4 6.37 Basic
pKa5 2.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H2 receptor GPCR ANTAGONIST Kd 7.93 WOMBAT-PK CHEMBL
Heat shock protein HSP 90-alpha Cytosolic other IC50 5.30 WOMBAT-PK
Solute carrier family 22 member 3 Transporter IC50 4.97 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.44 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 4.44 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 6.12 CHEMBL
Histamine H2 receptor GPCR Kd 7 CHEMBL

External reference:

IDSource
4017970 VUID
N0000146320 NUI
D00318 KEGG_DRUG
4017970 VANDF
C0015620 UMLSCUI
CHEBI:4975 CHEBI
FO9 PDB_CHEM_ID
CHEMBL902 ChEMBL_ID
DB00927 DRUGBANK_ID
3325 PUBCHEM_CID
D015738 MESH_DESCRIPTOR_UI
7074 IUPHAR_LIGAND_ID
5217 INN_ID
5QZO15J2Z8 UNII
4278 RXNORM
41331 MMSL
4713 MMSL
d00141 MMSL
003417 NDDF
387211002 SNOMEDCT_US
39128000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Famotidine HUMAN OTC DRUG LABEL 1 0093-2748 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Good Sense Dual Action Complete HUMAN OTC DRUG LABEL 3 0113-0032 TABLET, CHEWABLE 10 mg ORAL ANDA 15 sections
good sense acid reducer HUMAN OTC DRUG LABEL 1 0113-0141 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Good Sense Acid Reducer HUMAN OTC DRUG LABEL 1 0113-0194 TABLET, FILM COATED 20 mg ORAL ANDA 15 sections
basic care acid reducer HUMAN OTC DRUG LABEL 1 0113-7141 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Basic Care famotidine HUMAN OTC DRUG LABEL 1 0113-7194 TABLET, FILM COATED 20 mg ORAL ANDA 14 sections
basic care dual action complete HUMAN OTC DRUG LABEL 3 0113-7321 TABLET, CHEWABLE 10 mg ORAL ANDA 15 sections
Famotidine HUMAN PRESCRIPTION DRUG LABEL 1 0172-5728 TABLET, FILM COATED 20 mg ORAL ANDA 25 sections
Famotidine HUMAN PRESCRIPTION DRUG LABEL 1 0172-5729 TABLET, FILM COATED 40 mg ORAL ANDA 25 sections
Pepcid HUMAN PRESCRIPTION DRUG LABEL 1 0187-4420 TABLET, FILM COATED 20 mg ORAL ANDA 25 sections
Pepcid HUMAN PRESCRIPTION DRUG LABEL 1 0187-4440 TABLET, FILM COATED 40 mg ORAL ANDA 25 sections
Famotidine HUMAN PRESCRIPTION DRUG LABEL 1 0338-5197 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 22 sections
Acid ControllerOriginal Strength HUMAN OTC DRUG LABEL 1 0363-0141 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Acid Controller Completedual action HUMAN OTC DRUG LABEL 3 0363-0321 TABLET, CHEWABLE 10 mg ORAL ANDA 15 sections
Acid Reducer Complete HUMAN OTC DRUG LABEL 3 0363-0511 TABLET, CHEWABLE 10 mg ORAL ANDA 15 sections
Acid Controller HUMAN OTC DRUG LABEL 1 0363-0701 TABLET, FILM COATED 20 mg ORAL ANDA 15 sections
Acid Reducer Complete HUMAN OTC DRUG LABEL 3 0363-0713 TABLET, CHEWABLE 10 mg ORAL ANDA 15 sections
Famotidine Human OTC Drug Label 1 0363-4400 TABLET, FILM COATED 10 mg ORAL ANDA 16 sections
Famotidine Human OTC Drug Label 1 0363-5300 TABLET, FILM COATED 20 mg ORAL ANDA 16 sections
Rugby Famotidine HUMAN OTC DRUG LABEL 1 0536-1298 TABLET, FILM COATED 20 mg ORAL ANDA 15 sections
DUO Fusion HUMAN OTC DRUG LABEL 3 0597-0315 TABLET, CHEWABLE 10 mg ORAL ANDA 13 sections
DUO Fusion HUMAN OTC DRUG LABEL 3 0597-0320 TABLET, CHEWABLE 10 mg ORAL ANDA 13 sections
Famotidine HUMAN PRESCRIPTION DRUG LABEL 1 0615-4582 TABLET, FILM COATED 20 mg ORAL ANDA 20 sections
Famotidine HUMAN PRESCRIPTION DRUG LABEL 1 0615-8301 TABLET, FILM COATED 40 mg ORAL ANDA 20 sections
Famotidine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6021 INJECTION 10 mg INTRAVENOUS ANDA 22 sections
Famotidine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6022 INJECTION 10 mg INTRAVENOUS ANDA 22 sections
Famotidine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6023 INJECTION 10 mg INTRAVENOUS ANDA 22 sections
heartburn relieforiginal strength HUMAN OTC DRUG LABEL 1 0904-5529 TABLET 10 mg ORAL ANDA 15 sections
Major Heartburn ReliefMaximum Strength HUMAN OTC DRUG LABEL 1 0904-5780 TABLET, FILM COATED 20 mg ORAL ANDA 15 sections
Famotidine HUMAN PRESCRIPTION DRUG LABEL 1 10544-481 TABLET 20 mg ORAL ANDA 21 sections